<i><b>-Majority of patients treated with telaprevir received a 24-week
regimen-</b></i>
<br />
<i><b>-6.9% and 7.7% treatment discontinuation rates due to adverse
events in 12- and 8-week telaprevir-based treatment arms -- lower than
previous telaprevir trials-</b></i>
<br />
<i><b>-First Phase 3 trial results for a direct acting antiviral therapy
in hepatitis C-</b></i>
<br />
<i>-17% of people achieved SVR with pegylated-interferon and ribavirin
alone in the control arm-</i>
<br />
<i>-Safety and tolerability results were consistent with prior Phase 3
studies-</i>
<br />
<i>-Completion of rolling New Drug Application submission on track for
the fourth quarter 2010-</i>
<br />
<i>-56% of prior treatment null responder patients achieved SVR with a
48-week telaprevir-based regimen-</i>
<br />
<i>-97% of prior treatment relapsers and 55% of prior treatment partial
responders achieved SVR with 24-week or 48-week telaprevir-based
regimens-</i>
<br />
48-Week Efficacy Comparison of Lexiva/Ritonavir QD vs. Nelfinavir BID in Therapy-Naive HIV+ Patients: Results Published in AIDS Research Triangle Park, NC, July 8, 2004 -- The protease inhibitor (PI) LEXIVA(R) (fosamprenavir calcium) dosed with ritonavir (LEXIVA/r) once-daily (QD) as part of a
